Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 4 of 10« First...23456...10...Last »

Novartis AG Rejects Trump’s Proposition to Create More U.S Jobs

Toward the end of January 2017, U.S. President Donald Trump held a meeting with executives from several big pharmaceutical companies and the head of PhRMA, the industry lobbying group. Trump pushed for lower drug prices in the U.S., and urged the companies to create more jobs in the U.S. For the most part, industry chief executives have kept their opinions to themselves, at least publicly. However, in interviews with Der Landbote and Bernet Zeitung newspapers, Joe Jimenez, chief executive officer of Novartis and head of PhRMA, responded to both key points.

Read More »

After weeks of secrecy, U.S. Senate to unveil healthcare bill

U.S. Senate Republicans plan to unveil the text of their draft healthcare bill as senators struggle over issues such as the future of the Medicaid program for the poor and bringing down insurance costs.

Read More »

U.S. Supreme Court ruling threatens massive talc litigation against J&J

Johnson & Johnson is seizing upon a U.S. Supreme Court ruling limiting where injury lawsuits can be filed to fight off claims it failed to warn women that talcum powder could cause ovarian cancer.

Read More »

Coconut oil has more ‘bad’ fat than beef and butter: heart doctors

Coconut oil raises ‘bad’ cholesterol in the same way as other foods high in saturated fats like butter and beef, according to the American Heart Association.

Read More »

Worldwide drug sale forecasts fall as pricing pressures mount

Forecasts for global sales of pharmaceuticals have declined for the first time in a decade as continuing pressure on prices in the key U.S. market has caused analysts to moderate revenue expectations, according to a report.

Read More »

FDA Approves Cotempla XR-ODT For ADHD

The FDA approved Neos’ Cotempla XR-ODT, the first methylphenidate extended-release orally disintegrating tablet for treating ADHD in patients 6 to 17 years old.

Read More »

A Look at the 5 Most Profitable Biopharma Companies

Although a stock price does not always correlate to profitability, for bigger biopharma companies, profitability is a positive thing. Keith Speights, writing for The Motley Fool, takes a look at the five big pharma companies with the highest net margins in the industry.

Read More »

Parexel Sold to Investment Firm in $5 Billion Deal

Pamplona Capital Management, a private equity firm, is buying contract research organization Parexel International for a deal valued at about $5 billion.

Read More »

Novartis’ Next-Generation Eye Drug Works With Fewer Injections Than Rivals

Switzerland-based Novartis announced positive results from two Phase III trials, HAWK and HARRIER, of RTH258 in neovascular age-related macular degeneration (nAMD). In addition to being as effective as its nearest competitors, it requires fewer injections.

Read More »

FDA approves antibiotic for serious skin infections

The U.S. Food and Drug Administration approved a new treatment for patients with acute bacterial skin infections, made by privately held Melinta Therapeutics.

Read More »

The Piano Starts Softly and Slowly Builds …

There were 580 entries into this year’s Pharma category at Cannes Lions Health. That’s 580 case films accompanied by a slow, heart-wrenching solo piano track that begins with a few spare notes and builds to an optimistic outcome.

Read More »

Scientists find new biomarker to guide cancer immunotherapy

Scientists said they had pinpointed a particular type of immune system cell that could predict more precisely if cancer patients are likely to respond to modern immunotherapy medicines.

Read More »

Bayer Puts Down More Roots in Massachusetts With New Life Science Center

German-based life sciences giant Bayer AG is digging a deep foundation in the booming biotech hub of Boston.

Read More »

Clovis Oncology Ovarian Cancer Trial Dazzles

Clovis Oncology announced topline results from a confirmatory Phase III ARIEL3 trial of Rubraca (ruparib) in platinum-sensitive ovarian cancer.

Read More »

Seattle Genetics Halts Phase III Leukemia Study

Seattle Genetics halted all clinical trials of its vadastuximab talirine due to higher incidents of death associated with the treatment for AML patients.

Read More »

Publicis Health appoints Brion Brandes, EVP, Business Development

Publicis Health’s message delivery businesses announced that Brion Brandes has been named Executive Vice President of Business Development.

Read More »

Novartis throws down gauntlet to Roche with Rituxan copy

Switzerland’s Novartis increased pressure on Roche’s aging stable of big-selling drugs by becoming the latest company to win European approval for a cut-price version of Rituxan for blood cancer and immunological diseases.

Read More »

PerkinElmer to Acquire EUROIMMUN for Approximately $1.3 Billion

PerkinElmer Inc. announced that it has entered into a definitive agreement to acquire EUROIMMUN Medical Laboratory Diagnostics AG. The agreement provides that PerkinElmer will acquire up to a 100% stake in EUROIMMUN.

Read More »

New test may turn AstraZeneca’s Lynparza into precision drug for prostate cancer

Scientists have developed a new three-in-one blood test that has the potential to turn AstraZeneca’s drug Lynparza into a precision medicine for prostate cancer.

Read More »

Lions Health 2017: Pharma Winners

The Pharma winners were revealed at the Lions Health 2017 Awards Show.

Read More »

Page 4 of 10« First...23456...10...Last »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!

Subscribe

Ad Right Bottom

Main Navigation